JNJ-A07 | CAS#2135640-93-4 | NS3-NS4B interaction inhibitor

MedKoo Cat#: 466030 | Name: JNJ-A07

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNJ-A07 is a highly potent, orally active antiviral compound developed by Janssen Pharmaceutica, designed to inhibit dengue virus (DENV) replication across all four serotypes. It exhibits nanomolar to picomolar activity against a diverse panel of 21 clinical DENV isolates, demonstrating broad-spectrum efficacy .

Chemical Structure

JNJ-A07

CAS#2135640-93-4

Theoretical Analysis

MedKoo Cat#: 466030

Name: JNJ-A07

CAS#: 2135640-93-4

Chemical Formula: C28H26ClF3N2O6

Exact Mass: 578.1431

Molecular Weight: 578.97

Elemental Analysis: C, 58.09; H, 4.53; Cl, 6.12; F, 9.84; N, 4.84; O, 16.58

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 850.00	2 Weeks
10mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

JNJ-A07; JNJA07; JNJ A07;

IUPAC/Chemical Name

(S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid

InChi Key

WUBVXTOLZKVNEG-SANMLTNESA-N

InChi Code

InChI=1S/C28H26ClF3N2O6/c1-38-22-13-20(14-23(15-22)39-12-2-3-25(35)36)33-26(18-4-7-19(29)8-5-18)27(37)34-11-10-17-6-9-21(16-24(17)34)40-28(30,31)32/h4-9,13-16,26,33H,2-3,10-12H2,1H3,(H,35,36)/t26-/m0/s1

SMILES Code

COC1=CC(OCCCC(O)=O)=CC(N[C@@H](C2=CC=C(Cl)C=C2)C(N3C(C=C(OC(F)(F)F)C=C4)=C4CC3)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 578.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mendoza M, Ireland DDC, Lee HN, Kelly-Baker L, Chowdhury M, Verthelyi D, Manangeeswaran M. CpG oligodeoxynucleotides and pan-serotype inhibitors control neurotropic Dengue infection in novel immune competent neonatal mouse model. Emerg Microbes Infect. 2025 Mar 10:2477668. doi: 10.1080/22221751.2025.2477668. Epub ahead of print. PMID: 40059770. 2: Rosales-Rosas AL, Goossens S, Chiu W, Majumder A, Soto A, Masyn S, Stoops B, Wang L, Kaptein SJF, Goethals O, Delang L. The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding. Sci Adv. 2024 Nov 29;10(48):eadr8338. doi: 10.1126/sciadv.adr8338. Epub 2024 Nov 27. PMID: 39602538; PMCID: PMC11601208. 3: Lee Y, Seo M, Yun SH, Yu M, Kim HJ, Cho HW, Byeon HW, Park SO, Uyangaa E, Jeon H, Lee M, Kwon YD, Eo SK. Inhibitory peptides derived from Hepatitis C virus NS5A for reducing clinical symptoms of dengue virus infection. Antiviral Res. 2024 Nov;231:106018. doi: 10.1016/j.antiviral.2024.106018. Epub 2024 Oct 9. PMID: 39389166. 4: Kiemel D, Kroell AH, Denolly S, Haselmann U, Bonfanti JF, Andres JI, Ghosh B, Geluykens P, Kaptein SJF, Wilken L, Scaturro P, Neyts J, Van Loock M, Goethals O, Bartenschlager R. Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation. Nat Commun. 2024 Jul 19;15(1):6080. doi: 10.1038/s41467-024-50437-3. PMID: 39030239; PMCID: PMC11271582. 5: Goethals O, Voge NV, Kesteleyn B, Chaltin P, Jinks T, De Marez T, Koul A, Draghia-Akli R, Neyts J, Van Loock M. A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public- private partnerships. Antiviral Res. 2023 Feb;210:105495. doi: 10.1016/j.antiviral.2022.105495. Epub 2022 Dec 22. PMID: 36567021; PMCID: PMC9902276. 6: Behnam MAM, Klein CD. Corona versus Dengue: Distinct Mechanisms for Inhibition of Polyprotein Processing by Antiviral Drugs. ACS Pharmacol Transl Sci. 2022 Jun 24;5(7):508-511. doi: 10.1021/acsptsci.2c00105. PMID: 35837137; PMCID: PMC9274768. 7: Kaptein SJF, Goethals O, Kiemel D, Marchand A, Kesteleyn B, Bonfanti JF, Bardiot D, Stoops B, Jonckers THM, Dallmeier K, Geluykens P, Thys K, Crabbe M, Chatel-Chaix L, Münster M, Querat G, Touret F, de Lamballerie X, Raboisson P, Simmen K, Chaltin P, Bartenschlager R, Van Loock M, Neyts J. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature. 2021 Oct;598(7881):504-509. doi: 10.1038/s41586-021-03990-6. Epub 2021 Oct 6. Erratum in: Nature. 2021 Nov;599(7883):E2. doi: 10.1038/s41586-021-04123-9. PMID: 34616043.